Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

NCT07700966 is registered in ClinicalTrials.gov with Abeona Therapeutics, Inc as lead sponsor.

NCT NCT07700966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07700966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting
Lead sponsor
Abeona Therapeutics, Inc
Phase
Observational
Overall status
Recruiting
Start date
July 25, 2025
Completion date
April 30, 2045
Enrollment
250 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

recessive dystrophic epidermolysis bullosa